AACR 2026 – San Diego: Highlights and Event Recap

The AACR Annual Meeting 2026 was held in San Diego, CA, from April 17–22, 2026, bringing together global leaders in cancer research, drug development, and translational medicine. AACR showcased advances in tumor biology, immunotherapy, precision medicine, and emerging therapeutic modalities, with a strong focus on translating mechanistic insights into next-generation cancer therapies. 

→ Biointron’s Highlighted Points:

1. ADCs are shifting toward multi-functional payloads (immune, signaling, degradation) in addition to cytotoxicity 

2. Antibody therapeutics are converging with protein degradation and proximity pharmacology 

3. The tumor microenvironment is a primary target space

4. Clinical antibody development is becoming biomarker- and combination-first by design

1. Next-Generation Antibody Modalities

• Immune-stimulating ADCs (ISACs) designed to activate local immune responses

• Kinase inhibitor-based ADCs enabling targeted intracellular pathway modulation

• Degrader-antibody conjugates (DACs) enabling cell-selective protein degradation

• Shift toward event-driven mechanisms (induce degradation/interactions) vs. traditional inhibition

2. Immuno-Oncology Antibodies: New Targets Emerging

• Clinical-stage antibodies targeting CCR8 and IGSF8, expanding beyond classical checkpoints

• Dual-target strategies (e.g., integrin αvβ8/αvβ1) for multi-pathway modulation

• New antibodies positioned as add-ons to PD-1/PD-L1 backbones

3. Tumor Microenvironment as a Direct Target

• Macrophage-targeting strategies shifting toward functional reprogramming instead of depletion

• Fibroblast heterogeneity identified as a driver of therapy response and resistance

• ECM remodeling linked to drug penetration, immune exclusion, and metastasis

• Antibody targets expanding to stromal and non-tumor compartments

4. Antibodies and Cell Therapy

• Logic-gated immune cells introducing programmable, antibody-like targeting systems

• NK cell therapies adopting targeting strategies aligned with antibody engineering 

• Increasing overlap between antibody design and engineered cell therapies

5. Biomarkers Shifting to Functional Readouts

• ADC development incorporating functional response biomarkers

• Spatial multi-omics enabling in situ mapping of target expression and immune context

• ctDNA and dynamic biomarkers used for real-time treatment monitoring

6. Resistance-Driven Combination Strategies

• Resistance mechanisms (e.g., RAS, Hippo/YAP pathways) informing upfront combination design

• Combinations (antibody + IO + targeted therapy) becoming standard development strategy

• Shift from sequential therapy → designed multi-agent regimens

7. Convergence with Protein Degradation & New Modalities

• Emergence of DACs, RIPTACs, and proximity-based therapeutics

• Antibodies increasingly used as targeted delivery systems for novel mechanisms

• Expansion toward previously undruggable intracellular targets

8. Data-Driven Antibody Discovery

• AI-enabled single-cell and 3D tumor mapping informing target discovery

• Integration of multimodal data (genomics, imaging, clinical) to guide therapy design and stratification

• Shift toward data-first discovery workflows

Thank you to everyone who visited our booth at AACR 2026 to learn about our services! We had a fantastic time chatting with you and how it can help you achieve antibody development. Our expert team would be happy to answer any follow-up questions. Feel free to email us at info@biointron.com or visit our website at www.biointron.com.